Transgene (LTS:0OCQ) Accounts Payable & Accrued Expense : €13.20 Mil (As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is Transgene Accounts Payable & Accrued Expense?

Transgene's quarterly accounts payable & accrued expense increased from Dec. 2023 (€8.24 Mil) to Jun. 2024 (€10.93 Mil) and increased from Jun. 2024 (€10.93 Mil) to Dec. 2024 (€13.20 Mil).

Transgene's annual accounts payable & accrued expense declined from Dec. 2022 (€10.57 Mil) to Dec. 2023 (€8.24 Mil) but then increased from Dec. 2023 (€8.24 Mil) to Dec. 2024 (€13.20 Mil).

Transgene Accounts Payable & Accrued Expense Historical Data

The historical data trend for Transgene's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Transgene Accounts Payable & Accrued Expense Chart

Transgene Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

8.86

12.16

10.57

8.24

13.20

Transgene Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															10.57	9.92	8.24	10.93	13.20

Transgene Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Transgene Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Transgene SA (LTS:0OCQ) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

TRGNF:USA TNG:France TGNA:Germany

Address

400, Boulevard Gonthier d’Andernach, Parc d’Innovation, Illkirch-Graffenstaden, Strasbourg, FRA, 67400

Website

https://www.transgene.fr

Transgene SA is a biotechnology company that designs and develops targeted immunotherapy products for cancer. Transgene's programs utilize viral vector technology with the goal of indirectly or directly killing infected or cancerous cells. The company's portfolio of products in clinical development includes TG4050, an individualized therapeutic vaccine based on the myvac platform, TG4001, a therapeutic vaccine for HPV positive cancers, as well as BT-001 and TG6050, two oncolytic viruses based on the Invir.IO viral backbone. Transgene has several other programs in clinical and pre-clinical development that are based on its core viral vector technology. Geographically, the majority of its operations are located in France.

Transgene Headlines

No Headlines